Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant, for Patients with Cervical Cancer and Intermediate Pathologic Risk Factors By Ogkologos - September 24, 2025 483 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NRG Oncology/GOG-263/KGOG1008 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Study Identifies Potential Drug Target to Prevent Some Liver Cancers February 4, 2022 New on NCI Websites for July 2019 July 2, 2019 Being Diagnosed With a Childhood Cancer As an Adult Led Me... May 18, 2023 Understanding the Risk of Second Cancers After CAR T-Cell Therapy August 13, 2024 Load more HOT NEWS Trial Establishes Preferred Treatment for Some People with Esophageal Cancer EMA Recommends Granting a Marketing Authorisation for Generic Dasatinib Experimental Medulloblastoma Treatment Gets a Boost with Nanoparticles Why Wearing Comfortable Clothes During Cancer Treatment Matters
